BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy

Published:December 20, 2017DOI:
      Inactivating mutations in BRCA1 or BRCA2 predict response to PARP inhibitors and platinum-based chemotherapeutics. However, acquired secondary reversion mutations in BRCA1/2 that underlie resistance to these therapies have been identified in multiple tumor types.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Byrski T.
        • Huzarski T.
        • Dent R.
        • et al.
        Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients.
        Breast Cancer Res Treat. 2009; 115: 359-363
        • Isakoff S.J.
        • Mayer E.L.
        • He L.
        • et al.
        TBCRC009: A multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer.
        J Clin Oncol. 2015; 33: 1902-1909
        • Kaye S.B.
        • Lubinski J.
        • Matulonis U.
        • et al.
        Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.
        J Clin Oncol. 2012; 30: 372-379
        • Swisher E.M.
        • Lin K.K.
        • Oza A.M.
        • et al.
        Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
        Lancet Oncol. 2017; 18: 75-87
        • Tutt A.
        • Robson M.
        • Garber J.E.
        • et al.
        Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
        Lancet. 2010; 376: 235-244
        • Dhillon K.K.
        • Bajrami I.
        • Taniguchi T.
        • et al.
        Synthetic lethality: the road to novel therapies for breast cancer.
        Endocr Relat Cancer. 2016; 23: T39-T55
        • Barber L.J.
        • Sandhu S.
        • Chen L.
        • et al.
        Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor.
        J Pathol. 2013; 229: 422-429
        • Christie E.L.
        • Fereday S.
        • Doig K.
        • et al.
        Reversion of BRCA1/2 germline mutations detected in circulating tumor DNA from patients with high-grade serous ovarian cancer.
        J Clin Oncol. 2017; 35: 1274-1280
        • Edwards S.L.
        • Brough R.
        • Lord C.J.
        • et al.
        Resistance to therapy caused by intragenic deletion in BRCA2.
        Nature. 2008; 451: 1111-1115
        • Norquist B.
        • Wurz K.A.
        • Pennil C.C.
        • et al.
        Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.
        J Clin Oncol. 2011; 29: 3008-3015
        • Patch A.M.
        • Christie E.L.
        • Etemadmoghadam D.
        • et al.
        Whole-genome characterization of chemoresistant ovarian cancer.
        Nature. 2015; 521: 489-494
        • Sakai W.
        • Swisher E.M.
        • Karlan B.Y.
        • et al.
        Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.
        Nature. 2008; 451: 1116-1120
        • Swisher E.M.
        • Sakai W.
        • Karlan B.Y.
        • et al.
        Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.
        Cancer Res. 2008; 68: 2581-2586
        • Mayor P.
        • Gay L.M.
        • Lele S.
        • et al.
        BRCA1 reversion mutation acquired after treatment identified by liquid biopsy.
        Gynecol Oncol Rep. 2017; 21: 57-60
        • Afghahi A.
        • Timms K.M.
        • Vinayak S.
        • et al.
        Tumor BRCA1 reversion mutation arising during neoadjuvant platinum-based chemotherapy in triple-negative breast cancer is associated with therapy resistance.
        Clin Cancer Res. 2017; 23: 3365-3370
        • Waks A.G.
        • Cohen O.
        • Helvie K.
        • et al.
        Mechanisms of resistance (MoR) to DNA damaging therapy (tx) in BRCA1/2-deficient (d) metastatic breast cancer (MBC).
        J Clin Oncol. 2016; 34 (abstract 542)
        • Weigelt B.
        • Comino-Mendez I.
        • de Bruijn I.
        • et al.
        Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer.
        Clin Cancer Res. 2017; 23: 6708-6720
        • Pishvaian M.J.
        • Biankin A.V.
        • Bailey P.
        • et al.
        BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.
        Br J Cancer. 2017; 116: 1021-1026
        • Goodall J.
        • Mateo J.
        • Yuan W.
        • et al.
        Circulating free DNA to guide prostate cancer treatment with PARP inhibition.
        Cancer Discov. 2017; 7: 1006-1047
        • Quigley D.
        • Alumkal J.J.
        • Wyatt A.W.
        • et al.
        Analysis of circulating cell-free DNA identifies multi-clonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors.
        Cancer Discov. 2017; 7: 999-1006
        • Savas P.
        • Teo Z.L.
        • Lefevre C.
        • et al.
        The subclonal architecture of metastatic breast cancer: results from a prospective community-based rapid autopsy program “CASCADE”.
        PLoS Med. 2016; 13: e1002204
        • Chu D.
        • Paoletti C.
        • Gersch C.
        • et al.
        ESR1 mutations in circulating plasma tumor DNA from metastatic breast cancer patients.
        Clin Cancer Res. 2016; 22: 993-999
        • Kondrashova O.
        • Nguyen M.
        • Shield-Artin K.
        • et al.
        Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma.
        Cancer Discov. 2017; 7: 984-998
        • Drean A.
        • Williamson C.T.
        • Brough R.
        • et al.
        Modeling therapy resistance in BRCA1/2-mutant cancers.
        Mol Cancer Ther. 2017; 16: 2022-2034
        • Johnson S.F.
        • Cruz C.
        • Greifenberg A.K.
        • et al.
        CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer.
        Cell Rep. 2016; 17: 2367-2381
        • Yalon M.
        • Tuval-Kochen L.
        • Castel D.
        • et al.
        Overcoming resistance of cancer cells to PARP-1 inhibitors with three different drug combinations.
        PLoS One. 2016; 11: e0155711
        • Robinson D.R.
        • Wu Y.M.
        • Vats P.
        • et al.
        Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
        Nat Genet. 2013; 45: 1446-1451
        • Toy W.
        • Shen Y.
        • Won H.
        • et al.
        ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.
        Nat Genet. 2013; 45: 1439-1445
        • Chandarlapaty S.
        • Chen D.
        • He W.
        • et al.
        Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial.
        JAMA Oncol. 2016; 2: 1310-1315
        • Fribbens C.
        • O'Leary B.
        • Kilburn L.
        • et al.
        Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer.
        J Clin Oncol. 2016; 34: 2961-2968
        • Jeselsohn R.
        • Yelensky R.
        • Buchwalter G.
        • et al.
        Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer.
        Clin Cancer Res. 2014; 20: 1757-1767
        • Schiavon G.
        • Hrebien S.
        • Garcia-Murillas I.
        • et al.
        Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.
        Sci Transl Med. 2015; 7: 313ra182
        • Sefrioui D.
        • Perdrix A.
        • Sarafan-Vasseur N.
        • et al.
        Short report: monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer.
        Int J Cancer. 2015; 137: 2513-2519
        • Spoerke J.M.
        • Gendreau S.
        • Walter K.
        • et al.
        Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.
        Nat Commun. 2016; 7: 11579
        • Atchley D.P.
        • Albarracin C.T.
        • Lopez A.
        • et al.
        Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
        J Clin Oncol. 2008; 26: 4282-4288
        • Comen E.
        • Davids M.
        • Kirchhoff T.
        • et al.
        Relative contributions of BRCA1 and BRCA2 mutations to “triple-negative” breast cancer in Ashkenazi women.
        Breast Cancer Res Treat. 2011; 129: 185-190
        • Lakhani S.R.
        • Van De Vijver M.J.
        • Jacquemier J.
        • et al.
        The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.
        J Clin Oncol. 2002; 20: 2310-2318
        • Robson M.E.
        • Im S.
        • Senkus E.
        • et al.
        Olaparib for metastatic breast cancer in patients with a germline BRCA mutation.
        N Engl J Med. 2017; 377: 523-533